A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing.

Trial Profile

A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2014

At a glance

  • Drugs Entinostat (Primary) ; Aromatase inhibitors
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ENCORE-303
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 25 to 28.
    • 31 Mar 2011 Results will be presented at a scientific conference in 2011, according to a Syndax Pharmaceuticals media release.
    • 04 Jun 2010 Primary endpoint 'Clinical benefit rate' has been met, according to a Syndax Pharmaceuticals media release commenting on final results presented at the 2010 Annual Meeting of ASCO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top